Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
The last decade has seen a dramatic shift in anticancer drug research towards agents that aim to selectively target key regulatory and signaling processes known to drive tumorigenesis. A number of these newer agents have now been introduced into clinical practice. This volume reviews advances in cancer chemotherapy research over the last 10 years and will be of interest to scientists engaged in drug research in the pharmaceutical industry, biotechnology and startup companies, academia and government institutions. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs, including anti-hormonal therapy, growth factor inhibition, survival signaling, cell cycle inhibition, anti-angiogenics and anti-nvasives. Each chapter aims to cover the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.
Overview.- Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer.- Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK.- Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic.- Survival Signaling.- Progress in the Development of Agents to Control the Cell Cycle.- HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit.- Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy.- Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy.- Bcr-Abl Kinase Inhibitors.